Xin Chen

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses	2024	Jingyi Zhang Ruitao Lin Xin Chen Fangrong Yan
+	MIDAS-2: an enhanced Bayesian platform design for immunotherapy combinations with subgroup efficacy exploration	2023	Liwen Su Xin Chen Jingyi Zhang Fangrong Yan
+ PDF Chat	Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges	2023	Xin Chen Ruyue He Xinyi Chen Liyun Jiang Fei Wang
+	A comparative study of adaptive trial designs for dose optimization	2023	Jingyi Zhang Xin Chen Bosheng Li Fangrong Yan
+ PDF Chat	IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy	2023	Xin Chen Jingyi Zhang Liyun Jiang Fangrong Yan
+	Error Reduction from Stacked Regressions	2023	Xin Chen Jason M. Klusowski Tan Yan
+	Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses	2022	Xin Chen Jingyi Zhang Liyun Jiang Fangrong Yan
+	Bayesian two‐stage sequential enrichment design for biomarker‐guided phase II trials for anticancer therapies	2022	Liwen Su Xin Chen Jingyi Zhang Jun Gao Fangrong Yan
+ PDF Chat	Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials	2022	Liwen Su Xin Chen Jingyi Zhang Fangrong Yan
+	Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors	2022	Xin Chen Jingyi Zhang Qian Jiang Fangrong Yan
+	Containing Acute Disease Outbreak	2005	Arden K. Prince Xin Chen K. C. Lun

Common Coauthors

Coauthor	Papers Together
Fangrong Yan	8
Jingyi Zhang	6
Liyun Jiang	3
Liwen Su	3
Jason M. Klusowski	1
Bosheng Li	1
Fei Wang	1
Xinyi Chen	1
Jingyi Zhang	1
Qian Jiang	1
Tan Yan	1
Ruyue He	1
Jun Gao	1
K. C. Lun	1
Jingyi Zhang	1
Arden K. Prince	1
Ruitao Lin	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	5
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan	4
+	Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes	2003	Peter F. Thall J. Kyle Wathen B. Nebiyou Bekele Richard E. Champlin Laurence H. Baker Robert S. Benjamin	4
+ PDF Chat	BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies	2020	Ruitao Lin Yanhong Zhou Fangrong Yan Daniel Li Ying Yuan	4
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer	4
+ PDF Chat	A Bayesian basket trial design using a calibrated Bayesian hierarchical model	2018	Yiyi Chu Ying Yuan	4
+	Bayesian basket trial design with exchangeability monitoring	2018	Brian P. Hobbs Rick Landin	3
+ PDF Chat	A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes	2020	Ruitao Lin Peter F. Thall Ying Yuan	3
+	A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies	2019	Yanhong Zhou J. Jack Lee Ying Yuan	3
+ PDF Chat	Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials	2013	Scott Berry Kristine Broglio Susan Groshen Donald A. Berry	3
+ PDF Chat	Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials	2017	Fangrong Yan Sumithra J. Mandrekar Ying Yuan	3
+	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes	2018	Nan Chen J. Jack Lee	3
+	Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials	2009	Guosheng Yin Ying Yuan	3
+	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints	2020	Nan Chen J. Jack Lee	3
+	Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper)	2006	Andrew Gelman	3
+ PDF Chat	Time-to-event model-assisted designs for dose-finding trials with delayed toxicity	2019	Ruitao Lin Ying Yuan	3
+	Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials	2022	Ruitao Lin Haolun Shi Guosheng Yin Peter F. Thall Ying Yuan Christopher R. Flowers	2
+	Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy	2021	Liyun Jiang Ruobing Li Fangrong Yan Timothy A. Yap Ying Yuan	2
+	Incorporating historical information to improve phase I clinical trials	2021	Yanhong Zhou J. Jack Lee Shunguang Wang Stuart Bailey Ying Yuan	2
+	Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata	2020	Mo Li Rachael Liu Jianchang Lin Veronica Bunn Hongyu Zhao	2
+	Summarizing historical information on controls in clinical trials	2010	Beat Neuenschwander Gorana Capkun-Niggli Michael Branson David J. Spiegelhalter	2
+ PDF Chat	An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes	2019	Ruitao Lin Peter F. Thall Ying Yuan	2
+	PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials	2020	Yimei Li Ying Yuan	2
+ PDF Chat	A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative Controlled Clinical Studies	2015	Junlong Li Lihui Zhao Lü Tian Tianxi Cai Brian Claggett Andrea Callegaro Benjamin Dizier Bart Spiessens Fernando Ulloa‐Montoya L. J. Wei	2
+ PDF Chat	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy	2020	Haiyan Zheng James Wason	2
+ PDF Chat	Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials	2018	Ying Yuan Ruitao Lin Daniel Li Lei Nie Katherine E. Warren	2
+ PDF Chat	Phase I–II Trial Design for Biologic Agents Using Conditional Auto-Regressive Models for Toxicity and Efficacy	2018	Daniel G. Muenz Jeremy M. G. Taylor Thomas M. Braun	2
+ PDF Chat	Bayesian hierarchical modeling based on multisource exchangeability	2017	Alexander Kaizer Joseph S. Koopmeiners Brian P. Hobbs	2
+ PDF Chat	Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials	2021	Liyun Jiang Lei Nie Fangrong Yan Ying Yuan	2
+	The Drug-Dosing Conundrum in Oncology — When Less Is More	2021	Mirat Shah Atiqur Rahman Marc R. Theoret Richard Pazdur	2
+	Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials	2016	Ying Yuan Kenneth R. Hess Susan G. Hilsenbeck Mark R. Gilbert	2
+	ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage	2018	Rui Tang Shen Jing Ying Yuan	2
+ PDF Chat	Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities	2000	Ying Kuen Cheung Rick Chappell	2
+ PDF Chat	Accelerated Titration Designs for Phase I Clinical Trials in Oncology	1997	Richard Simon Larry Rubinstein Susan G. Arbuck Michaele C. Christian Boris Freidlin Jerry M. Collins	2
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks	2
+	Bridging continual reassessment method for phase I clinical trials in different ethnic populations	2015	Suyu Liu Haitao Pan Jielai Xia Qin Huang Ying Yuan	2
+	Robust meta‐analytic‐predictive priors in clinical trials with historical control information	2014	Heinz Schmidli Sandro Gsteiger Satrajit Roychoudhury Anthony O’Hagan David J. Spiegelhalter Beat Neuenschwander	2
+	Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset	2007	Sue‐Jane Wang Robert T. O’Neill Hung Hung	2
+	Robust exchangeability designs for early phase clinical trials with multiple strata	2015	Beat Neuenschwander Simon Wandel Satrajit Roychoudhury Stuart Bailey	2
+	Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios	2006	Guosheng Yin Yisheng Li Yuan Ji	2
+	Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs	2004	Peter F. Thall John D. Cook	2
+ PDF Chat	Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding	2017	Fangrong Yan Peter F. Thall K.H. Lu Mark R. Gilbert Ying Yuan	2
+	BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes	2018	Kentaro Takeda Masataka Taguri Satoshi Morita	2
+	Comparative review of novel model‐assisted designs for phase I clinical trials	2018	Heng Zhou Thomas A. Murray Haitao Pan Ying Yuan	2
+ PDF Chat	Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes	2012	Peter F. Thall Hoang Q. Nguyen	2
+	Borrowing Information across Subgroups in Phase II Trials: Is It Useful?	2013	Boris Freidlin Edward L. Korn	2
+ PDF Chat	Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization	2016	Marie‐Karelle Riviere Ying Yuan Jacques-Henri Jourdan Frédéric Dubois Sarah Zohar	2
+ PDF Chat	Adjusting for misclassification in a stratified biomarker clinical trial	2014	Chunling Liu Aiyi Liu Jiang Hu Vivian W.S. Yuan Susan Halabi	1
+ PDF Chat	Adaptive choice of patient subgroup for comparing two treatments	2014	Tze Leung Lai Philip W. Lavori Olivia Yueh-Wen Liao	1
+	Theoretical study of the continual reassessment method	2005	John O’Quigley	1